Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
Pharvaris presented positive Phase 3 data for deucrictibant at the EAACI 2026 Congress, highlighting rapid symptom relief and a novel 'End of Progression' endpoint. In the RAPIDe-3 trial, deucrictibant achieved a median time to symptom relief of 1.28 hours and complete resolution in 11.95 hours, with 83% of attacks treated with a single capsule. Long-term prophylaxis data from the CHAPTER-1 extension study showed a ~92% reduction in attack frequency and sustained improvement in quality of life over ~34 months.
Key figures
- Drug Name
- deucrictibant
- Phase Of Trial
- Phase 3
- Cv safety participants
- ~570
- Eop within 12 hours rate
- 92.8%
- No rescue medication rate
- 93.2%
- Long term attack reduction
- ~92%
- Single capsule treatment rate
- 83.0%
- Median time to symptom relief hours
- 1.28
- Median time to complete resolution hours
- 11.95
- Median time to end of progression minutes
- 17.47
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.